amineptine
Sign in to saveAlso known as Survector
Amineptine, formerly sold under the brand name Survector among others, is an atypical antidepressant of the tricyclic antidepressant (TCA) family. It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine reuptake inhibitor.
Research
287 papers- Amineptine and midazolam dependence.Singapore medical journal · 1998
- Pharmacology of amineptine: synthesis and updating.Clinical neuropharmacology · 1989
- Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.Journal of clinical psychopharmacology · 2009
- Early onset of action of amineptine.International clinical psychopharmacology · 1997
- Amineptine dependence.JPMA. The Journal of the Pakistan Medical Association · 1994
via PubMed
~9 min read
Encyclopedic overview
22 sectionsContents
- Medical uses
- Contraindications
- Precautions for use
- Effects on the fetus
- Side effects
- Dermatological
- Psychiatric
- Abuse and dependence
- Withdrawal
- Cardiovascular
- Hepatic
- Gastrointestinal
- Immunological
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Society and culture
- Brand names
- Legal status
- Research
- Wakefulness
- References
Amineptine, formerly sold under the brand name Survector among others, is an atypical antidepressant of the tricyclic antidepressant (TCA) family. It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine reuptake inhibitor.
Amineptine was developed by the French Society of Medical research in the 1960s. Introduced in France in 1978 by the pharmaceutical company Servier, amineptine soon gained a reputation for abuse due to its short-lived, but pleasant, stimulant effect experienced by some patients.
Excerpted from Wikipedia’s “amineptine” article, available under the CC BY-SA 4.0 licence.